Enveda, a biotech startup focused on uncovering drug candidates from plants and microbes through artificial intelligence, has closed a $311 million Series E round. The financing, led by Catalio Capital Management with involvement from Iconiq and others, values the company at $2 billion—double what it was worth just a year ago. The new capital aims to accelerate Enveda’s efforts to move nature-derived compounds into human trials.
From Nature to the Clinic via AI
Founded in 2019 by Viswa Colluru, who previously worked at Recursion Pharmaceuticals, Enveda builds AI-based platforms that scan nature’s molecular diversity—plants, fungi, microbes—to discover bioactive compounds. The goal is to cut down on the time and expense typically required for natural product drug discovery by applying machine learning and computational tools.
Though no AI-discovered drug has yet gained FDA approval, Enveda is among several emerging companies pushing forward into human testing. Its current pipeline includes candidates for a severe skin disease and another designed to help people maintain weight loss once they stop taking GLP-1 medications.
Financing and Ambitions
The $311 million came through a Series E round led by Catalio, with participation from Iconiq and additional investors. At $2 billion, Enveda’s valuation reflects growing confidence in AI’s potential to reshape how new medicines are discovered.
The funds are expected to support Enveda in advancing its natural-product drug candidates through clinical stages. With several molecules already in early patient trials, the company can now scale up research, streamline regulatory efforts, and potentially bring new therapies closer to market.
Natural product drug discovery has long been a source of successful therapies, but its traditional processes are slow, labor intensive, and complex. Enveda’s approach—marrying deep natural libraries with computational prediction—represents a trend of biotech companies leaning on AI to unlock compounds that might otherwise stay hidden.
This traction arrives at a time when AI in drug discovery has moved beyond hype and into proof-of-concept. Enveda is placing bets in high-need therapeutic areas, like maintaining weight loss post-GLP-1 treatment and treating severe skin conditions, showing how AI can target both novel and pressing medical challenges.
Why this matters: Enveda’s funding marks a milestone in AI-powered natural product biotech. It signals investor belief not just in drug discovery broadly, but in leveraging nature’s chemical diversity through computational methods. Keep an eye on how fast Enveda—alongside competitors—can deliver verifiable clinical outcomes. With multiple candidates in human trials, regulatory approvals or clinical setbacks in the coming 12-24 months will go a long way in defining whether AI’s role in natural drug discovery shifts from promise to practice.
